相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
Shogo Kumagai et al.
CANCER CELL (2022)
Immunotherapy of Cancer by Targeting Regulatory T cells
Bo-Jin Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
Lipid signalling enforces functional specialization of Treg cells in tumours
Seon Ah Lim et al.
NATURE (2021)
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Rebekka Duhen et al.
NATURE COMMUNICATIONS (2021)
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
Joseph R. Campbell et al.
CANCER RESEARCH (2021)
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
Murat Tekguc et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
Haiping Wang et al.
NATURE IMMUNOLOGY (2020)
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells
Shogo Kumagai et al.
IMMUNITY (2020)
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
Luis Felipe Campesato et al.
NATURE COMMUNICATIONS (2020)
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai et al.
NATURE IMMUNOLOGY (2020)
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
Isabelle Solomon et al.
NATURE CANCER (2020)
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Yoshihiro Ohue et al.
CANCER SCIENCE (2019)
Treg-mediated acquired resistance to immune checkpoint inhibitors
Reem Saleh et al.
CANCER LETTERS (2019)
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Toshihiko Doi et al.
CLINICAL CANCER RESEARCH (2019)
Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target
Neda Mousavi-Niri et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
T-Regulatory Cells In Tumor Progression And Therapy
Amit Verma et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
Varun Sasidharan Nair et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
Emerging targets in cancer immunotherapy
Samantha Burugu et al.
SEMINARS IN CANCER BIOLOGY (2018)
Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice
Z. Zhang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Remy Thomas et al.
FRONTIERS IN IMMUNOLOGY (2018)
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Ayman Oweida et al.
CLINICAL CANCER RESEARCH (2018)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models
Zhen Lu et al.
JOURNAL OF HEPATOLOGY (2017)
Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells
Sharee A. Basdeo et al.
JOURNAL OF IMMUNOLOGY (2017)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
Jin Hai Zheng et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
Marianne Davies et al.
IMMUNOTARGETS AND THERAPY (2017)
Resistance to PD1/PDL1 checkpoint inhibition
Jake S. O'Donnell et al.
CANCER TREATMENT REVIEWS (2017)
Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells
Selvakumar Sukumar et al.
CANCER RESEARCH (2017)
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Alessia Angelin et al.
CELL METABOLISM (2017)
Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma
Lei Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
Shamim Ahmad et al.
CANCER RESEARCH (2017)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Jason D. Fontenot et al.
JOURNAL OF IMMUNOLOGY (2017)
Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity
Mitesh Dwivedi et al.
AUTOIMMUNITY REVIEWS (2016)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2016)
Targeting regulatory T cells in tumors
Chang Liu et al.
FEBS JOURNAL (2016)
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
Marco De Simone et al.
IMMUNITY (2016)
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
George Plitas et al.
IMMUNITY (2016)
Roles of regulatory T cells in cancer immunity
Yoshiko Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2016)
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Melanie Ruf et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice
Neda Mousavi Niri et al.
JOURNAL OF IMMUNOTHERAPY (2016)
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Michael J. Flynn et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
Yuta Kondo et al.
ORAL ONCOLOGY (2016)
Adenosine can thwart antitumor immune responses elicited by radiotherapy Therapeutic strategies alleviating protumor ADO activities
Peter Vaupel et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2016)
Silencing of Foxp3 delays the growth of murine melanomas and modifies the tumor immunosuppressive environment
Moises A. Franco-Molina et al.
ONCOTARGETS AND THERAPY (2016)
Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer
Ho Kyoung Hwang et al.
ONCOLOGY LETTERS (2016)
PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer
Honggeng Guan et al.
SCIENTIFIC REPORTS (2016)
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
Wei-Wei Deng et al.
ONCOIMMUNOLOGY (2016)
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Alan Serrels et al.
CELL (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants
Veronica De Rosa et al.
NATURE IMMUNOLOGY (2015)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Selecting probiotics with the abilities of enhancing GLP-1 to mitigate the progression of type 1 diabetes in vitro and in vivo
Shih-Hung Wei et al.
JOURNAL OF FUNCTIONAL FOODS (2015)
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Bin Shang et al.
SCIENTIFIC REPORTS (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
Xiao Ni et al.
CLINICAL CANCER RESEARCH (2015)
VISTA Regulates the Development of Protective Antitumor Immunity
Isabelle Le Mercier et al.
CANCER RESEARCH (2014)
Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells
Hiromasa Morikawa et al.
IMMUNOLOGICAL REVIEWS (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Effect of HIF1α on Foxp3 expression in CD4+CD25- T lymphocytes
Jianguo Wu et al.
MICROBIOLOGY AND IMMUNOLOGY (2014)
Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals
Yuka Maeda et al.
SCIENCE (2014)
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Hye Sun Kuehn et al.
SCIENCE (2014)
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Andrew J. S. Furness et al.
TRENDS IN IMMUNOLOGY (2014)
A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling
Yufeng Xie et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
PD-1 is a novel regulator of human B-cell activation
Marie-Laure Thibult et al.
INTERNATIONAL IMMUNOLOGY (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Blockade of Programmed Death-1 in Young (New Zealand Black x New Zealand White)F1 Mice Promotes the Suppressive Capacity of CD4+ Regulatory T Cells Protecting from Lupus-like Disease
Maida Wong et al.
JOURNAL OF IMMUNOLOGY (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Kaori Sakuishi et al.
ONCOIMMUNOLOGY (2013)
Serine, glycine and one-carbon units: cancer metabolism in full circle
Jason W. Locasale
NATURE REVIEWS CANCER (2013)
Roles of LAG3 and EGR2 in regulatory T cells
Tomohisa Okamura et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
T Cell Receptor Stimulation-Induced Epigenetic Changes and Foxp3 Expression Are Independent and Complementary Events Required for Treg Cell Development
Naganari Ohkura et al.
IMMUNITY (2012)
Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
Takashi Ishida et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Wiebke Hansen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Regulatory T Cells Increase the Avidity of Primary CD8+ T Cell Responses and Promote Memory
Luigia Pace et al.
SCIENCE (2012)
Increased numbers of Foxp3-positive regulatory T cells in gastritis, peptic ulcer and gastric adenocarcinoma
Hsin-Hung Cheng et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells
Julien Faget et al.
CANCER RESEARCH (2011)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
Thymus, innate immunity and autoimmune arthritis: Interplay of gene and environment
Shimon Sakaguchi et al.
FEBS LETTERS (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human
Fabian Birzele et al.
NUCLEIC ACIDS RESEARCH (2011)
Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma
Katjana Klages et al.
CANCER RESEARCH (2010)
LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
Chiara Camisaschi et al.
JOURNAL OF IMMUNOLOGY (2010)
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Joshua D. Mezrich et al.
JOURNAL OF IMMUNOLOGY (2010)
T-regulatory cell modulation: the future of cancer immunotherapy?
S. Nizar et al.
BRITISH JOURNAL OF CANCER (2009)
Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy
B. S. Dwarakanath et al.
FUTURE ONCOLOGY (2009)
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Ethan M. Shevach
IMMUNITY (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
Cytotoxicity,radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose In vitro
B. S. Dwarakanath
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
Jeffrey M. Wilson et al.
JOURNAL OF IMMUNOLOGY (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio:: Which variable determines survival of cervical cancer patients?
Ekaterina S. Jordanova et al.
CLINICAL CANCER RESEARCH (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages
Machteld M. Tiemessen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
S. Audia et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with stage and survival
L. M. Gjerdrum et al.
LEUKEMIA (2007)
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Lauren W. Collison et al.
NATURE (2007)
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance
Xuefang Cao et al.
IMMUNITY (2007)
Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses
Siguo Hao et al.
JOURNAL OF IMMUNOLOGY (2007)
Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor
Tomoyuki Yamaguchi et al.
IMMUNITY (2007)
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
Qiang Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients
Junliang Fu et al.
GASTROENTEROLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells
Antonio Curti et al.
BLOOD (2007)
FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis
Noritoshi Kobayashi et al.
CLINICAL CANCER RESEARCH (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity
Smita Nair et al.
CANCER RESEARCH (2007)
Tumor-derived CD4(+) CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10
Nicolas Larmonier et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients
Rebecca P. Petersen et al.
CANCER (2006)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism
Fabienne Venet et al.
JOURNAL OF IMMUNOLOGY (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn et al.
BLOOD (2006)
Suppression of antitumor immunity by IL-10 and TGF-β-producing T cells infiltrating the growing tumor:: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells
Andrew G. Jarnicki et al.
JOURNAL OF IMMUNOLOGY (2006)
Prospects for exosomes in immunotherapy of cancer
G. Mignot et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2006)
Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck
K Sakakura et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
CD4(+)CD25(high) regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
Koji Kono et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients
P Correale et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer
D Wolf et al.
CLINICAL CANCER RESEARCH (2005)
Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte
SJ Gardai et al.
CELL (2005)
Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K Ko et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
M Beyer et al.
BLOOD (2005)
Optimizing cancer radiotherapy with 2-deoxy-D-glucose - Dose escalation studies in patients with glioblastoma multiforme
DH Singh et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2005)
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients
H Nishikawa et al.
BLOOD (2005)
Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts
H Nishikawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells
E Unitt et al.
HEPATOLOGY (2005)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
LA Ormandy et al.
CANCER RESEARCH (2005)
Characteristics of CD4+ CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
C Schaefer et al.
BRITISH JOURNAL OF CANCER (2005)
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors
P Yu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Distribution of CD4(+)CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer
H Kawaida et al.
JOURNAL OF SURGICAL RESEARCH (2005)
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2
PA Antony et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells
T Alvaro et al.
CLINICAL CANCER RESEARCH (2005)
Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells
CL Berger et al.
BLOOD (2005)
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells
DH Munn et al.
JOURNAL OF IMMUNOLOGY (2004)
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
NA Marshall et al.
BLOOD (2004)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction
P Trzonkowski et al.
CLINICAL IMMUNOLOGY (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells
M Viguier et al.
JOURNAL OF IMMUNOLOGY (2004)
Expression of FoxP3, a key molecule in CD4+CD25+ regulatory T cells, in adult T-cell leukaemia/lymphoma cells
K Karube et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients
A Fattorossi et al.
GYNECOLOGIC ONCOLOGY (2004)
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+ CD25+ T cells
GL Stephens et al.
JOURNAL OF IMMUNOLOGY (2004)
Tumor-specific human CD4(+) regulatory T cells and their ligands: Implications for immunotherapy
HY Wang et al.
IMMUNITY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies -: Possible involvement of regulatory T cells in disease progression
T Sasada et al.
CANCER (2003)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2003)
CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice
SE Erdman et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
CD4(+)CD25(+) regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice
DM Xu et al.
JOURNAL OF IMMUNOLOGY (2003)
CD4(+)CD25(+) T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner
W Janssens et al.
JOURNAL OF IMMUNOLOGY (2003)
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses
M Kursar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
UK Liyanage et al.
JOURNAL OF IMMUNOLOGY (2002)
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation
EY Woo et al.
JOURNAL OF IMMUNOLOGY (2002)
The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells
SJ Seo et al.
IMMUNITY (2002)
Monitoring CD8 T cell responses to NY-ESO-1:: Correlation of humoral and cellular immune responses
E Jäger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
